1. Home
  2. FURY vs OTLK Comparison

FURY vs OTLK Comparison

Compare FURY & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fury Gold Mines Limited

FURY

Fury Gold Mines Limited

HOLD

Current Price

$0.50

Market Cap

115.8M

ML Signal

HOLD

Logo Outlook Therapeutics Inc.

OTLK

Outlook Therapeutics Inc.

BUY

Current Price

$0.56

Market Cap

249.6M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
FURY
OTLK
Founded
2008
2010
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
115.8M
249.6M
IPO Year
2011
2016

Fundamental Metrics

Financial Performance
Metric
FURY
OTLK
Price
$0.50
$0.56
Analyst Decision
Buy
Buy
Analyst Count
2
4
Target Price
$1.90
★ $5.03
AVG Volume (30 Days)
247.0K
★ 3.7M
Earning Date
11-12-2026
08-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 55.91
EPS
★ N/A
N/A
Revenue
N/A
★ $8,146,123.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$6,355.64
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$0.16
52 Week High
$1.02
$2.54

Technical Indicators

Market Signals
Indicator
FURY
OTLK
Relative Strength Index (RSI) 37.90 44.61
Support Level N/A $0.53
Resistance Level $0.57 $0.72
Average True Range (ATR) 0.02 0.05
MACD -0.00 0.00
Stochastic Oscillator 7.17 67.05

Price Performance

Historical Comparison
FURY
OTLK

About FURY Fury Gold Mines Limited

Fury Gold Mines Ltd is a Canadian-focused high-grade gold exploration company. The company's projects are strategically positioned in two prolific mining regions: the Eeyou Istchee James Bay Region of Quebec and the Kitikmeot Region in Nunavut. Fury Gold's project portfolio comprises the Committee Bay gold project in Nunavut, and the Eau Claire gold, Sakami gold, Elmer East gold and lithium, and Eleonore South gold projects in Quebec. Additionally, it also owns interests in the Kipawa rare earths project and has full ownership of the Zeus heavy rare earths project, both located in the Temiscamingue region of Quebec. The company operates in two reportable segments: Quebec and Nunavut.

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Share on Social Networks: